Professor, Pediatrics, USC School of Medicine

Pediatric Hematology & Oncology

Robert Seeger works in the field of Pediatric Hematology & Oncology. He went to Oregon Health & Science University School of Medicine. He received awards:"Super Doctor". Robert Seeger is a published doctor as well. He has 44 publications published. The latest was: A novel minimal residual disease model of neuroblastoma in mice.

Publications

---

• A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
• Drugging MYCN through an Allosteric Transition in Aurora Kinase A.
• Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group.
• Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
• Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma.
• Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
• Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Onco...
• Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
• The genetic landscape of high-risk neuroblastoma.
• Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma.
• Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
• Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
• Immunology and immunotherapy of neuroblastoma.
• Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
• Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
• Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology ...
• NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
• Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.
• ATM is down-regulated by N-Myc-regulated microRNA-421.
• Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
• Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
• Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
• ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.
• Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncol...
• Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.
• Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplant...
• An integrated cross-platform prognosis study on neuroblastoma patients.
• Molecular characterization of the pediatric preclinical testing panel.
• Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.
• De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene.
• Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
• Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
• The MYCN enigma: significance of MYCN expression in neuroblastoma.
• Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a n...
• Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
• Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subt...
• TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
• GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma.
• Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2.
• Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.
• Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on F...
• A novel minimal residual disease model of neuroblastoma in mice.
• MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Schools

---

• Oregon Health And Science University School Of Medicine

• University Minn Hosps

• National Institute Of Health

• University College

Doctors Specialties

---

• Pediatrics
• Pediatric Hematology
• Oncology

Accepted Insurances

---

Awards

---

• Super Doctor

Education

---

• University of Minnesota at Fairview
• Oregon Health & Science University School of Medicine

Hospital

---

• Children's Hospital Los Angeles

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Roy L. Kao, MD This Doctor is OpenDoctor Recommended.
	Dr. Norma Perez, MD
	Dr. Rashmi Sekhon, MD This Doctor is OpenDoctor Recommended.
	Dr. Antonio Zamora, MD This Doctor is OpenDoctor Recommended.
	Dr. Sheena L. Kamra, MD
	Dr. Casey V. Strier, MD This Doctor is OpenDoctor Recommended.
	Dr. Philippe Champagne, MD This Doctor is OpenDoctor Recommended.
	Dr. Shruti S. Nagaraj, MD
	Dr. Jonathan L. Finlay, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Ruby P. Kalra, MD This Doctor is OpenDoctor Recommended.
	Dr. Susan McKenna, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephen A. Feig, MD This Doctor is OpenDoctor Recommended.
	Dr. Josephine H. Haduong, MD This Doctor is OpenDoctor Recommended.
	Girish Dhall, MB This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Alan Ikeda, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog